Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지
DOI QR코드

DOI QR Code

The value of prophylactic cranial irradiation in limited-stage small cell lung cancer: should it always be recommended?

  • Koh, Minji (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Song, Si Yeol (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jo, Ji Hwan (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Park, Geumju (Department of Radiation Oncology, Inje University Haeundae Paik Hospital) ;
  • Park, Jae Won (Department of Radiation Oncology, Yeungnam University Medical Center) ;
  • Kim, Su Ssan (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Choi, Eun Kyung (Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2019.06.12
  • Accepted : 2019.07.22
  • Published : 2019.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Prophylactic cranial irradiation (PCI) is a standard treatment for limited-stage small cell lung cancer (LS-SCLC) showing a response to initial treatment, but many patients do not receive PCI due to comorbidities or refusal. This study aims to define the patient group for whom PCI can be omitted with minimal risk. Materials and Methods: Patients with LS-SCLC who underwent radiotherapy with curative aim at our institution between January 2004 and December 2015 were retrospectively reviewed. Patients who did not receive PCI were evaluated for brain metastasis-free survival (BMFS), progression-free survival (PFS), overall survival (OS), and prognostic factors for survival, and treatment outcomes were compared with a patient cohort who received PCI. Results: A total of 350 patients achieved a response following thoracic radiotherapy, and 190 of these patients did not receive PCI. Stage I-II and a complete response (CR) to initial therapy were good prognostic factors for BMFS and OS on univariate analysis. Patients with both stage I-II and a CR who declined PCI showed comparable 2-year BMFS to those who received PCI (92% vs. 89%). In patients who achieved CR, PCI did not significantly improve OS or PFS. Conclusion: There should be less concern about omitting PCI in patients with comorbidities if they have stage I-II or a CR, with brain metastasis control being comparable to those patients who receive PCI.

Keywords

References

  1. Gaspar LE, McNamara EJ, Gay EG, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer 2012;13:115-22. https://doi.org/10.1016/j.cllc.2011.05.008
  2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-44. https://doi.org/10.1200/JCO.2005.04.4859
  3. Komaki R, Cox JD, Whitson W. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation. Cancer Treat Rep 1981;65:811-4.
  4. Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer 2001;1:5. https://doi.org/10.1186/1471-2407-1-5
  5. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999;341:476-84. https://doi.org/10.1056/NEJM199908123410703
  6. Kalemkerian GP, Loo BW, Akerley W, et al. NCCN Guidelines Insights: small cell lung cancer, version 2.2018. J Natl Compr Canc Netw 2018;16:1171-82. https://doi.org/10.6004/jnccn.2018.0079
  7. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. Eur J Cancer 1997;33:1752-8. https://doi.org/10.1016/S0959-8049(97)00135-4
  8. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:77-84. https://doi.org/10.1016/j.ijrobp.2010.05.013
  9. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183-90. https://doi.org/10.1093/jnci/87.3.183
  10. Giuliani M, Sun A, Bezjak A, et al. Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. Cancer 2010;116:5694-9. https://doi.org/10.1002/cncr.25341
  11. Lok BH, Ma J, Foster A, et al. Factors influencing the utilization of prophylactic cranial irradiation in patients with limitedstage small cell lung cancer. Adv Radiat Oncol 2017;2:548-54. https://doi.org/10.1016/j.adro.2017.08.001
  12. Zheng Y, Wang L, Zhao W, et al. Risk factors for brain metastasis in patients with small cell lung cancer without prophylactic cranial irradiation. Strahlenther Onkol 2018;194:1152-62. https://doi.org/10.1007/s00066-018-1362-7
  13. Sakaguchi M, Maebayashi T, Aizawa T, Ishibashi N, Saito T. Treatment outcomes of patients with small cell lung cancer without prophylactic cranial irradiation. J Thorac Dis 2016;8:2571-9. https://doi.org/10.21037/jtd.2016.08.73
  14. Wu AJ, Gillis A, Foster A, et al. Patterns of failure in limitedstage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation. Radiother Oncol 2017;125:130-5. https://doi.org/10.1016/j.radonc.2017.07.019
  15. Gong L, Wang QI, Zhao L, Yuan Z, Li R, Wang P. Factors affecting the risk of brain metastasis in small cell lung cancer with surgery: is prophylactic cranial irradiation necessary for stage I-III disease? Int J Radiat Oncol Biol Phys 2013;85:196-200. https://doi.org/10.1016/j.ijrobp.2012.03.038
  16. Ogawa S, Horio Y, Yatabe Y, et al. Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer. Int J Clin Oncol 2012;17:218-24. https://doi.org/10.1007/s10147-011-0277-4
  17. Sun JM, Ahn YC, Choi EK, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol 2013;24:2088-92. https://doi.org/10.1093/annonc/mdt140
  18. Manapov F, Niyazi M, Gerum S, et al. Evaluation of the role of remission status in a heterogeneous limited disease small-cell lung cancer patient cohort treated with definitive chemoradiotherapy. BMC Cancer 2016;16:216. https://doi.org/10.1186/s12885-016-2245-x
  19. Lu H, Fang L, Wang X, Cai J, Mao W. A meta-analysis of randomized controlled trials comparing early and late concurrent thoracic radiotherapy with etoposide and cisplatin/ carboplatin chemotherapy for limited-disease small-cell lung cancer. Mol Clin Oncol 2014;2:805-10. https://doi.org/10.3892/mco.2014.311
  20. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-60. https://doi.org/10.1200/JCO.2002.12.071
  21. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensivedisease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2017;18:663-71. https://doi.org/10.1016/S1470-2045(17)30230-9
  22. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664-72. https://doi.org/10.1056/NEJMoa071780
  23. Mamesaya N, Wakuda K, Omae K, et al. Efficacy of prophylactic cranial irradiation in patients with limiteddisease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy. Oncotarget 2018;9:17664-74. https://doi.org/10.18632/oncotarget.24830

Cited by

  1. Re-evaluation of prophylactic cranial irradiation in limited-stage small cell lung cancer: a propensity score matched analysis vol.62, pp.5, 2019, https://doi.org/10.1093/jrr/rrab053